The SMART healthcare solution
Journal Title: Advances in Precision Medicine - Year 2017, Vol 2, Issue 1
Abstract
Substitutable Medical Apps Reusable Technologies (SMARTĀ®) on Fast Healthcare Interoperability Resources (FHIR) is an open, standards platform that allows third parties to build health applications that interact with electronic health record (EHR) systems. This can allow for aggregation of unique data ranging from genomics to lifestyle, thereby promoting the emerging precision medicine approach. It is also the first to provide a way to successfully incorporate interoperability in EHRs and precision medicine implementation.
Authors and Affiliations
Basil H. Chaballout, Ryan J. Shaw , Karin Reuter-Rice
The role of open innovation in biomarker discovery
Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable...
The research data reproducibility problem solicits a 21st century solution
Reproducibility is a hallmark of scientific efforts. Estimates indicate that lack of reproducibility of data ranges from 50% to 90% among published research reports. The inability to reproduce major findings of published...
What makes a good biomarker?
The last decade has seen an extraordinary amount of effort devoted in biomedical research to the field of biomarkers. There have been some notable successes with novel markers being adopted into clinical practice bringin...
Genomics Vault: A framework for precision medicine data management
A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different...
Personalized medicine: consequences for drug research and therapy
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases....